sb 203580 has been researched along with ethidium in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (ethidium) | Trials (ethidium) | Recent Studies (post-2010) (ethidium) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 4,782 | 11 | 690 |
| Protein | Taxonomy | sb 203580 (IC50) | ethidium (IC50) |
|---|---|---|---|
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 2.0333 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boyfield, I; Fonfria, E; Humphrey, PP; Michel, AD; Simon, J; Thompson, KM | 1 |
1 other study(ies) available for sb 203580 and ethidium
| Article | Year |
|---|---|
Species and response dependent differences in the effects of MAPK inhibitors on P2X(7) receptor function.
Topics: Adenosine Triphosphate; Animals; Calcium Signaling; Cell Line; Cell Membrane Permeability; Dose-Response Relationship, Drug; Ethidium; Humans; Imidazoles; Indicators and Reagents; Interleukin-1beta; Membrane Potentials; Mice; Mitogen-Activated Protein Kinases; Monocytes; Protein Kinase Inhibitors; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2X7; Recombinant Fusion Proteins; Species Specificity; Transfection | 2006 |